Enhancing the Natriuretic Peptide System in HFpEF

Summary

The purpose of this study is to look at the differences in how individuals with heart failure with preserved ejection fraction in the presence of chronic kidney disease (HFpEF-CKD) and exercise induced dyspnea without objective findings of fluid retention (HFpEF-EI) bodies function using drugs Sacubatril/Valsartan (Entresto) and MANP.

Timeline

Start

2022-11-04

Primary completion

2027-04

Completion

2027-04

Drugs

Indications